DOI: 10.1136/gutjnl-2017-315766
,
,
PMID: 29331941
MEDLINE Status: Publisher
Issn Electronic: 1468-3288
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.
Célia Gouynou; Lieven Pouillon; Hélène Rousseau; Camille Zallot; Cédric Baumann; Laurent Peyrin-Biroulet
Author Information: Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Clinical Research Support Facility PARC, UMDS Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Clinical Research Support Facility PARC, UMDS Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.; Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France.
Checking for direct PDF access through Ovid |
Abstract
Abstract unavailable for this article.